BACKGROUND Pantoprazole sodium, a proton-pump inhibitor, is approved for the short-term treatment of several types of ulcer, Zollinger-Ellison syndrome, and gastroesophageal reflux disease. OBJECTIVE To determine the physical compatibility and chemical stability of ethylenediaminetetra-acetic acid (EDTA)-free pantoprazole in glass vials, polypropylene syringes, and polyvinylchloride (PVC) min...

background : proton pump inhibitors (ppis) are currently the most effective agents for acid related disorders. however, studies show that 25-75% of patients receiving intravenous pantoprazole had no appropriate justification, indicating high rate of inappropriate prescribing in hospitals. the aim of this study is to examine the appropriate use of intravenous pantoprazole in accordance with guid...

BACKGROUND Drug use evaluation is a performance improvement method that evaluates medication-use processes. Medication studies are especially important for drugs with narrow therapeutic index, specific indication, high costs as well as for drugs with widespread use. Intravenous pantoprazole always ranked among the top 5 costly drugs in Amir-al-Momenin Hospital. Considering the fact that widespr...

BACKGROUND/AIMS To evaluate the effectiveness of pantoprazole magnesium (pantoprazole-Mg) 40 mg in the relief of esophageal and extra-esophageal symptoms of gastroesophageal reflux disease (GERD), particularly night-time symptoms. METHODS Patients (aged 18-50 years) with 3-month history of heartburn and/or acid regurgitation plus at least one other symptom in the last week were enrolled in a ...

background: this study aimed to compare intermittent intravenous (iv) pantoprazole and ranitidine for control of gastric acid secretion and the possible prevention of upper gastrointestinal bleeding (ugib) in critical care patients. methods: this was a randomized, double blind clinical trial study of iv pantoprazole (40 mg every12 hour) or intermittent iv ranitidine (50 mg bolus every 8 hour) i...

Under normal physiological conditions, gastric acid production is controlled by a negative feedback mechanism. Proton pump inhibitors, such as pantoprazole, inhibit gastric acid secretion by irreversibly binding and inactivating luminally active hydrogen potassium ATPase. Recovery of acid production after treatment with a proton pump inhibitor is driven by new pump synthesis, activation of exis...

BACKGROUND In early 2009, 2 observational studies and a US Food and Drug Administration (FDA) advisory addressed the drug interaction between proton pump inhibitors (PPIs) and clopidogrel. One study suggested that pantoprazole could be used safely in this setting, whereas the other study and the FDA advisory did not distinguish among PPIs. We examined trends in PPI prescribing among clopidogrel...

Two modified coated membrane sensors were designed and tested. Pantoprazole-phosphotungstate was prepared by a reaction of pantoprazole with phosphotungstic acid in the solvent mediator o-nitrophenyloctyl ether. metal oxide nanoparticles nickel iron nanoparticles, synthesized from green sources Matricaria recutita flowers Salvia officinalis leaves extracts, respectively. These used for potentio...

Endoscopic submucosal dissection (ESD) has been reported to have a higher bleeding rate than conventional methods. However, there are few reports on whether a proton pump inhibitor or a histamine2-receptor antagonist is the more effective treatment for preventing bleeding after ESD. In a prospective trial, patients undergoing ESD due to gastric adenoma or adenocarcinoma were randomly assigned t...

OBJECTIVES This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel after coronary stenting for non-ST-segment elevation acute coronary syndrome (NSTE ACS). BACKGROUND Use of omeprazole has been reported to significantly decrease the clopidogrel antiplatelet effect because of cytochrome P450 interaction. Because all PPIs are metabolized by...